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January 2011264 Letters to the Editortion by using risk factors in the National Health and Nutrition
Examination Survey cohort rather than the more obvious extrap-
olation of data from the life line screening cohort.
This point demonstrates that robust predictive scores for
complex diseases should be based on data generated from longitu-
dinal population studies rather than selected cohorts such as this.
In addition, the majority of any individuals’ risk based on this score
that is explained by their age and smoking history, is the current
standard for selective screening in the United States. Virtually all of
the domains in the scoring system are related to atherosclerosis,
which may not be a causal process in AAAs and, therefore, may be
overrepresented in the score.5
Finally, the authors equate the efficiency of screening to the
prevalence of the disease in screened groups (number of screens per
AAA), but this is only one part of the cost-effectiveness equation. The
prognosis for aneurysmal disease is reduced in smokers and patients
with a high prevalence of cardiovascular disease, whichmay negatively
impact upon the cost-effectiveness of screening this group.6,7
Seamus Conor Harrison, MRCS
Steve Eric Humphries, PhD, FRCP
Centre for Cardiovascular Genetics
University College London Hospital
London, United Kingdom
REFERENCES
1. Kent KC, Zwolak RM, EgorovaNN, Riles TS,Manganaro A,Moskowitz
AJ, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort
of more than 3 million individuals. J Vasc Surg 2010;52:539-49.
2. AshtonHA, BuxtonMJ, Day NE, Kim LG,Marteau TM, Scott RA, et al.
The Multicentre Aneurysm Screening Study (MASS) into the effect of
abdominal aortic aneurysm screening on mortality in men: a randomised
controlled trial. Lancet 2002;360:1531-9.
3. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdom-
inal aortic aneurysms: a 7-year prospective study: the Tromsø Study,
1994-2001. Circulation 2009;119:2202-8.
4. Pleumeekers HJ, Hoes AW, van der Does E, van Urk H, Hofman A, de
Jong PT, et al. Aneurysms of the abdominal aorta in older adults. The
Rotterdam Study. Am J Epidemiol 1995;142:1291-9.
5. JohnsenSH,Forsdahl SH, SinghK, JacobsenBK.Atherosclerosis in abdom-
inal aortic aneurysms: a causal event or a process running in parallel? The
Tromsø study. Arterioscler Thromb Vasc Biol 2010;30:1263-8.
6. Hallett JW Jr, Bower TC, Cherry KJ, Gloviczki P, Joyce JW, Pairolero
PC. Selection and preparation of high-risk patients for repair of abdom-
inal aortic aneurysms. Mayo Clin Proc 1994;69:763-8.
7. Smoking, lung function and the prognosis of abdominal aortic aneurysm.




We thank the authors of this Letter to the Editor for sharing
their interesting comments on our study. In this letter, it is
suggested that the prevalence of abdominal aortic aneurysms
(AAAs) in our data set is lower than the prevalence observed in
other data sets, in that it reflects the provenance of our cohort from
an overall healthier population. Based on this observation, the
authors of the letter infer that the odds ratio derived from the
analysis of risk factors in our sample could be inflated when
extrapolated to the general population.
The discrepancy between the prevalence in our cohort and the
prevalence reported by other studies is mostly a consequence of the
high representation (64.7%) of women in our cohort, which on
average have a lower risk of AAAs as compared tomen.Other studies,
which report a prevalence of AAA around 4%, aremostly composed of
men. TheMulticentre Aneurysm Screening Study study, for example,
included only male subjects, and in the cohort of veterans from theAneurysm Detection and Management study, the proportion of
womenwas only 2.6%.1 In the subset of our cohort composed ofmale
subjects aged 65 to 79 years old, the prevalence of an AAA is 2.8%, a
figure more comparable to previously reported prevalence data.
Nonetheless, as we indicated in the discussion, we do not exclude the
possibility that our sample could be derived from a somewhat health-
ier group of people. However, this alone would not result in falsely
elevated odds ratios.Our cohort included a broad spectrumof specific
risk factors whose strength of association with AAA disease, as mea-
sured by the odds ratio, would not be affected if subjects at risk
were under-represented in the cohort.
Becausewe assumed thatwe could extrapolate the strengthof the
association between risk factors and disease to the general population,
but not the actual distribution of risk factors, we used estimates of risk
factors’ prevalence from theNationalHealth andNutrition Examina-
tion Survey dataset. By combining prevalence and distribution of risk
factors derived from National Health and Nutrition Examination
Survey with our estimates of the strength of association between risk
factors andAAA,wewere able tomake predictions of AAAprevalence
in the general population. We fully agree that, ideally, predictive
scores should be derived from longitudinal population studies. How-
ever, data sources based on longitudinal samples that are large enough
to enable robust predictions in different population subgroups do not
currently exist. The life line screening data set is a very rich data set
which permits to derive useful inferences about the relationship be-
tween risk factors and AAA disease, and that we believe have adjusted
sufficiently for potential selection bias. The resulting predictive score
clearly needs to be validated in another cohort with the aim of
generating the definitive risk prediction model.
As indicated by the authors of the Letter to the Editor, our
data are in line with current recommendations, by indicating that
age and smoking history along with male sex, are the most impor-
tant risk factors. However, current recommendations treat smok-
ing as a binary variable, even though it encompasses a broad
spectrum of risk that depends on differences in individual smoking
history. We have shown that the inclusion of smoking patterns
along with additional risk factors greatly enhances the efficiency of
selective screening as compared to current recommendations. Sim-
ilarly, the accuracy of our predictive model is enhanced by the
inclusion of additional risk factors, atherosclerosis-related and not.
The impact of each of these risk factors was fully adjusted for the
impact of the other risk factors. This is independent from the
nature of the relationship between atherosclerosis and AAA, which
cannot be clarified by multivariable analysis.
Finally, the authors of the letter are right in pointing out that
increasing the efficiency in the detection of AAA does not neces-
sarily translate in a more cost-effective screening program, given
the different prognoses and life expectancies of selected subjects
and the potential induced costs generated by the new selection
criteria. A cost-effectiveness analysis of the implementation of our
score is warranted and is a relevant next step, but it was beyond the
scope of this article.
Thank you again for stimulating a discussion on these impor-
tant issues.
Giampaolo Greco, PhD, MPH
Mount Sinai School of Medicine
Health Evidence and Policy
New York, NY
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Regarding “Asymptomatic carotid artery stenosis—
Medical therapy alone versus medical therapy plus
carotid endarterectomy or stenting”
Current medical intervention alone is now best for prevention of
stroke associated with asymptomatic carotid stenosis.1 Dr Schneider’s
case against this conclusion is fatally flawed because it is based on an
outdated, over-reliance on borderline significant results from histori-
cal randomized carotid endarterectomy (CEA) trials (“level 1 evi-
dence”) and underestimation of the counter-evidence.2,3
There have been significant falls in average annual rates of ipsilat-
eral and any territory stroke ( transient ischemic attack)withmedical
intervention alone since the early 1980s, with rates falling below those
of patients who received medical intervention and CEA in random-
ized trials.1 These falls were revealed after a thorough, systematic
literature analysis limited to prospective studies of100 patients with
direct-imaging-identified asymptomatic carotid stenosis of 50% or
75% using North American Symptomatic Carotid Endarterectomy
Trial (NASCET)/NASCET comparable measurements. There were
3724 patients, including those from randomized trials, with average
follow-up of about 3 to 4 years. Whether randomized to surgery or
not, patients had similar stenosis severity (50% or 60% in the
randomized trials, for example). Subsequent publications have been
consistent with a continuing drop in stroke event rates with current
medical intervention alone. The conclusion that current medical
intervention alone is now best for prevention of stroke associatedwith
asymptomatic severe carotid stenosis is based on all currently available
evidence; these published annual stroke rates, consideration of non-
stroke/death atherosclerotic complications, observations of routine
practice CEA, and cost.1
We need more measurements of the average annual risk of
stroke, and other major atherosclerotic complications, among
well-described patients with asymptomatic carotid stenosis receiv-
ing well-described current medical intervention alone. Current
commonplace and current best medical intervention are ever-evolving
concepts that will vary across time and locality. Therefore, we need
to make such measurements an ongoing, integral part of routine
practice around the world. We also need to keep defining current
best medical intervention by updating optimal ways to identify and
treat risk factors to best prevent clinical complications.
The average annual ipsilateral stroke rate amonghospital-referred
patients with asymptomatic severe carotid stenosis receiving current
medical intervention alone is now expected to be consistently 1%,
perhaps0.5%.Therefore, what clinical or economic benefit could be
expected for routine practice from further randomized trials of addi-
tional surgery/stenting in this setting? None! Instead, we need to
identify the small minority with sufficiently higher than average risk
despite current best medical intervention alone. We can expect such
patients will also be at higher risk from CEA/stenting. Therefore, we
would need to randomize them to additional CEA/stenting (and
only them!). The results of such randomized trials will not be available
for10 to 15 years. So, in the meantime, we should stop operating,
stop stenting, deliver better current best medical intervention, and
better measures!
Anne L. Abbott, MD, FRACP, PhD
Baker IDI Heart and Diabetes Institute
Victoria, Australia
National Stroke Research Institute
Melbourne, Australia
Dr Abbott’s research is supported by an Australian National
Health and Medical Research Council (NHMRC) post-doctoral
fellowship (ID 472700).REFERENCES
1. Abbott AL. Medical (nonsurgical) intervention alone is now best for
prevention of stroke associated with asymptomatic severe carotid steno-
sis: results of a systematic review and analysis. Stroke 2009;40:e573-83.
2. Schneider PA, Naylor AR. Asymptomatic carotid artery stenosis—medical
therapy alone versus medical therapy plus carotid endarterectomy or stent-
ing. J Vasc Surg 2010;52:499-507.
3. Schneider PA, Naylor AR. Asymptomatic carotid artery stenosis—medical
therapy alone versus medical therapy plus carotid endarterectomy or stent-
ing. J Vasc Endovasc Surg 2010;40:274-81.
doi:10.1016/j.jvs.2010.07.059
Reply
The letter from Dr Abbott adds nothing new, except perhaps a
bit of bluster. I need to know how to manage real live patients at risk
for stroke from severe asymptomatic carotid stenosis, and I am not
going to find out fromDrAbbott’s letter. The paper referenced in the
letter byDrAbbott as holding the answer to this problemwas cited by
both authors in the preceding debate.1 I encourage everyone to read
this paper cited by both debaters andby the letter fromDrAbbott and
examine the studies from which it is derived. Many of you will be
horrified with what you find; small, poorly controlled studies of
patients with no neurological examination, lots of crossovers, unclear
duplex findings, and many minor carotid lesions. We are being told
that this conclusion has been “discovered” through a review of these
earlier studies. The answer was apparently right there all the time; a
gold nugget in a boggy field.
The Asymptomatic Carotid Surgery Trial was better con-
ducted than any single study cited as a reason to abandon repair of
carotid stenosis.2 When have marginal studies, even a lot of them,
trumped level 1 evidence? When does a review paper hold the
answer while a well-conducted randomized controlled trial does
not? The debate was written prior to the publication of the Carotid
Revascularization Endarterectomy versus Stenting Trial but the
letter by Dr. Abbott was written since, with no moderation in
tone.3 Now we all know that asymptomatic patients had a periop-
erative stroke/death risk of 1.4% with endarterectomy. Suppose
the annual risk of stroke without repair is as low as 1% as has been
suggested (we still don’t know)? Any patient with a life expectancy
of more than a few years could still potentially benefit from repair.
It may come to pass that medical management solves this
problem; no doubt there is a trend. However, evidence being cited
that repair should be abandoned is not conclusive. Only the
convictions of the proponents of that nihilistic approach are clear.
How can anyone be so certain that it is time to abandon repair?
Peter A. Schneider, MD
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